2014 Conference Programme

trait-separation-idea-summit

1

2013-2014 Breakthroughs and innovations in the field of diabetes

plenary session

A general overview of the last findings in the field of diabetes that have occurred during the last months. The most important events, doctor the major breakthroughs might be summarized in order to answer the question “what has been done in diabetes for the last months?”
Different stakeholders will bear witness to their point of view.

Confirmed Speakers:

  • Tomas LANDH, pill Director Strategy and Innovation Sourcing, Diabetes Research Unit, NovoNordisk (Denmark)
  • Mickael Skjodt SORENSEN, Co-opted Board Member of the International Diabetes Federation Europe &Vice President of the Danish Diabetes Association (Denmark)
  • Sophie MEGNIEN, Chief Medical Officer, Genfit (France)
  • Bernard THORENS, Professor at the Center for integrative Genomics, University of Lausanne (Switzerland)
  • Michel PINGET, Professor, head of the Diabetology and Endocrinology at the Muller Hospital, President of theEuropean Center for the Study of Diabetes (France)

2

What do you expect as a good level of maturity of finding?
Too early stage for me guy!

track1

In research collaborations between academia and industries, differences in mutual expectations can result in that both parties are disappointed. Which type of basic and applied research fields (such as biology, target identification/validation, diagnostics, biomarkers) interest academia, biotech and pharma? Research institutes and biotech/pharma industry should define more clearly what are the strengths and expertise of each actor and when and how the translation between basic and applied research could start. Biotech and pharma should present actively what could be relevant starting points of collaboration, including data, intellectual property, goals and time-lines.

In order to facilitate constructive relationships between academia and industries and to accelerate the pace of innovation in diabetes, we have to understand what each actor expects from the others and to develop a strategy involving more team- and goal-oriented approach with defined and shared milestones.

Confirmed Speakers:

  • Christine REYNET, Director and co-Owner, McC+R&D Consulting Ltd (UK)
  • Jan OSCARSSON, Clinical Research Physician, Global Medicines DevelopmentAstraZeneca (Sweden)
  • Bart STAELS, Prof at the Faculty of Pharmacy, University of Lille 2, Director of the Inserm UMR1011 (France)
  • Florence DAL DEGAN, External Innovation, Zealand Pharma (Denmark)
  • Farzad ABDI-DEZFULI, Partner, Sarsia Seed Management AS (Norway)

3

Is stratified/personalized/precision medicine one of the paradigms on which we could grind our collective efforts for research in diabetes?

track2

Despite advances in pharmacology, not all patients respond favorably to drugs. Do we need to develop new drug generation? Actually there’s no innovative idea neither new target.
To cross out the lack of future innovative treatments, we need to develop an integrated approach that looks for patients and treatments and to adapt treatments to patient. In that way we don’t need only therapeutics results but also diagnostics results.

We trill try to answer the following questions:

  • What are so far the interesting of relevant subjects that have been hand out?
  • What is the value of stratified medicine in the field of diabetes? What is the reason why there are so few things?
  • What do diabetic patients, researchers and pharma expect
  • Is stratified medicine the right direction to take to improve diabetes care?
  • How can researchers and infrastructures address the remaining unmet clinical needs?

Confirmed Speakers:

  • Leif GROOP, Professor and Director of the Lund University Diabetes Centre (Sweden)
  • François PATTOU, Professor of General Surgery, Lille University & Head of department of General Endocrine Surgery, Lille University Hospital & Director of the INSERM UMR 859 (France)
  • Catherine LARUE, CEO, Integrated Biobank of Luxembourg (Luxembourg)
  • Marc DONATH, Professor of Endocrinology, Diabetes and Metabolism, University Hospital Basel(Switzerland)
  • Bernd JABLONKA, External Alliances, Diabetes Division, Sanofi (Germany)

4

Do we need a European joint diabetes research agenda? Who should contribute to it? What should be the goals of this joint research agenda?

track3

Despite advances in pharmacology, not all patients respond favorably to drugs. Do we need to develop new drug generation? Actually there’s no innovative idea neither new target.
To cross out the lack of future innovative treatments, we need to develop an integrated approach that looks for patients and treatments and to adapt treatments to patient. In that way we don’t need only therapeutics results but also diagnostics results.

We trill try to answer the following questions:

  • What are so far the interesting of relevant subjects that have been hand out?
  • What is the value of stratified medicine in the field of diabetes? What is the reason why there are so few things?
  • What do diabetic patients, researchers and pharma expect
  • Is stratified medicine the right direction to take to improve diabetes care?
  • How can researchers and infrastructures address the remaining unmet clinical needs?

Confirmed Speakers:

  • Leif GROOP, Professor and Director of the Lund University Diabetes Centre (Sweden)
  • François PATTOU, Professor of General Surgery, Lille University & Head of department of General Endocrine Surgery, Lille University Hospital & Director of the INSERM UMR 859 (France)
  • Catherine LARUE, CEO, Integrated Biobank of Luxembourg (Luxembourg)
  • Marc DONATH, Professor of Endocrinology, Diabetes and Metabolism, University Hospital Basel(Switzerland)
  • Bernd JABLONKA, External Alliances, Diabetes Division, Sanofi (Germany)

Continue your tour

trait-separation-idea-summit-2

HOSTED BY

logo_2016_biofit_reduit

trait-separation-biofit-3

30th Nov. – 1st Dec. 2016

Lille, FRANCE